Treatment of Helicobacter pylori infection 2011.

Hdl Handle:
http://hdl.handle.net/10147/207887
Title:
Treatment of Helicobacter pylori infection 2011.
Authors:
O'Connor, Anthony; Gisbert, Javier P; McNamara, Deirdre; O'Morain, Colm
Affiliation:
Department of Gastroenterology, Adelaide and Meath Hospital incorporating the, National Children's Hospital/Trinity College Dublin, Dublin, Ireland., jpoconno@tcd.ie
Citation:
Helicobacter. 2011 Sep;16 Suppl 1:53-8. doi: 10.1111/j.1523-5378.2011.00881.x.
Journal:
Helicobacter
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207887
DOI:
10.1111/j.1523-5378.2011.00881.x
PubMed ID:
21896086
Abstract:
This article reviews the literature published pertaining to Helicobacter pylori eradication over the last year. The general perception among clinicians and academics engaged in research on H. pylori has been that eradication rates for first-line therapies are falling, although some data published this year have cast doubt on this. The studies published this year have therefore focussed on developing alternative strategies for the first-line eradication of H. pylori. In this regard, clear evidence now exists that both levofloxacin and bismuth are viable options for first-line therapy. The sequential and "concomitant" regimes have also been studied in new settings and may have a role in future algorithms also. In addition, data have emerged that the probiotic Saccharomyces boulardii may be a useful adjunct to antibiotic therapy. Other studies promote individualized therapies based on host polymorphisms, age, and other such demographic factors.
Language:
eng
MeSH:
Anti-Bacterial Agents/*therapeutic use; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections/*drug therapy/genetics/microbiology; Helicobacter pylori/*drug effects; Humans; Probiotics/*therapeutic use; Proton Pump Inhibitors/*therapeutic use
ISSN:
1523-5378 (Electronic); 1083-4389 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Connor, Anthonyen_GB
dc.contributor.authorGisbert, Javier Pen_GB
dc.contributor.authorMcNamara, Deirdreen_GB
dc.contributor.authorO'Morain, Colmen_GB
dc.date.accessioned2012-02-01T10:49:10Z-
dc.date.available2012-02-01T10:49:10Z-
dc.date.issued2012-02-01T10:49:10Z-
dc.identifier.citationHelicobacter. 2011 Sep;16 Suppl 1:53-8. doi: 10.1111/j.1523-5378.2011.00881.x.en_GB
dc.identifier.issn1523-5378 (Electronic)en_GB
dc.identifier.issn1083-4389 (Linking)en_GB
dc.identifier.pmid21896086en_GB
dc.identifier.doi10.1111/j.1523-5378.2011.00881.xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207887-
dc.description.abstractThis article reviews the literature published pertaining to Helicobacter pylori eradication over the last year. The general perception among clinicians and academics engaged in research on H. pylori has been that eradication rates for first-line therapies are falling, although some data published this year have cast doubt on this. The studies published this year have therefore focussed on developing alternative strategies for the first-line eradication of H. pylori. In this regard, clear evidence now exists that both levofloxacin and bismuth are viable options for first-line therapy. The sequential and "concomitant" regimes have also been studied in new settings and may have a role in future algorithms also. In addition, data have emerged that the probiotic Saccharomyces boulardii may be a useful adjunct to antibiotic therapy. Other studies promote individualized therapies based on host polymorphisms, age, and other such demographic factors.en_GB
dc.language.isoengen_GB
dc.subject.meshAnti-Bacterial Agents/*therapeutic useen_GB
dc.subject.meshClinical Trials as Topicen_GB
dc.subject.meshDrug Therapy, Combinationen_GB
dc.subject.meshHelicobacter Infections/*drug therapy/genetics/microbiologyen_GB
dc.subject.meshHelicobacter pylori/*drug effectsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshProbiotics/*therapeutic useen_GB
dc.subject.meshProton Pump Inhibitors/*therapeutic useen_GB
dc.titleTreatment of Helicobacter pylori infection 2011.en_GB
dc.contributor.departmentDepartment of Gastroenterology, Adelaide and Meath Hospital incorporating the, National Children's Hospital/Trinity College Dublin, Dublin, Ireland., jpoconno@tcd.ieen_GB
dc.identifier.journalHelicobacteren_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.